To date several research groups have focused on developing compounds that target c-MYC for cancer therapy, whilst there have been only a few publications that have explored the possibility of targeting MYCN [27], [28], [39], [51], [52] The small molecule 10058-F4 has been extensively studied in the context of targeting c-MYC in cancer cells, although more information is needed regarding its true specificity [28], [30], [33], [34], [40]. This evidence concerns the gene MYCN and cancer.